免疫相关不良事件可预测癌症患者抗PD-1抗体的治疗疗效
研究纳入106例接受单药纳武利尤单抗或帕博利珠单抗治疗的晚期癌症患者,40例(37.7%)出现免疫相关不良事件(irAEs)。伴irAEs患者客观缓解率82.5%、中位无进展生存期10个月,不伴irAEs者分别为16.6%和3个月(OR 23.5,P<0.000001;HR 2.2,P=0.016)。总生存期两组无统计学显著差异。
要点
- 单药抗PD-1治疗的晚期癌症患者中irAEs发生率为37.7%(40/106)。
- 伴irAEs者客观缓解率82.5% vs 不伴者16.6%(OR 23.5,P<0.000001)。
- 伴irAEs者中位PFS 10个月 vs 不伴者3个月(HR 2.2,P=0.016)。
核心结论
- 在接受单药抗PD-1抗体治疗的晚期癌症患者中,出现irAEs的患者疗效明显优于未出现irAEs的患者(ORR 82.5%和中位PFS 10个月 vs ORR 16.6%和中位PFS 3个月)。
- 作者提出未来的抗PD-1免疫治疗研究应针对这一关联进一步探索疗效的潜在生物学机制。
研究设计与样本
- 研究为对接受单药纳武利尤单抗或帕博利珠单抗治疗的晚期癌症患者的分析,共纳入106例。
- irAEs经临床识别并按不良事件通用术语标准4.0版分级。
- 疗效采用免疫相关疗效评价标准(immune-RECIST)的客观缓解率、无进展生存期和总生存期评价。
- 采用检验分析irAEs与ORR、PFS或OS之间的关联。
主要发现
- 原发诊断包括肺癌77例、黑色素瘤8例、头颈癌7例、肾癌5例、霍奇金淋巴瘤3例、尿路上皮癌3例,以及胆囊腺癌、肝细胞癌和梅克尔细胞癌各1例。
- 40例(37.7%)观察到irAEs,最常见的irAEs为甲状腺功能减退15例、肾炎5例和甲状腺功能亢进4例。
- 44例(41.5%)观察到客观缓解,中位PFS为5.5个月(0.5-31个月)。
- 40例伴irAEs患者中33例有客观缓解(82.5%),而66例不伴irAEs者中11例有客观缓解(16.6%)(OR 23.5,P < 0.000001)。
- 伴irAEs患者PFS为10个月,不伴irAEs者为3个月(HR 2.2,P = 0.016);伴irAEs患者OS为32个月,不伴irAEs者为22个月,无统计学显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer immune therapy has shown remarkable benefit in the treatment of a range of cancer types, although it may initiate autoimmune-related disorders in some patients. We have attempted to establish whether the incidence of irAEs after the use of anti-PD-1 antibodies nivolumab or pembrolizumab in advanced malignancies is associated with anti-PD-1 treatment efficacy. PATIENTS AND METHODS: We studied patients treated with single-agent nivolumab or pembrolizumab for advanced cancer. irAEs (immune-related adverse events) were identified clinically and graded as per the Common Terminology Criteria for Adverse Events version 4.0. Efficacy was evaluated with objective response rate (ORR, immune-Response Evaluation Criteria in Solid Tumours [RECIST] criteria) progression-free survival (PFS) and overall survival (OS). Tests were performed to determine the association between irAEs and ORR, PFS or OS. RESULTS: We identified 106 patients. Primary diagnoses were lung cancer (n = 77), melanoma (n = 8), head and neck carcinoma (n = 7), renal carcinoma (n = 5), Hodgkin's lymphoma (n = 3), urothelial carcinoma (n = 3) and gallbladder adenocarcinoma, hepatocellular carcinoma and Merkel cell carcinoma (n = 1 each). IrAEs were observed in 40 patients (37.7%). The most frequent irAEs were hypothyroidism (n = 15), nephritis (n = 5) and hyperthyroidism (n = 4). Objective response was observed in 44 patients (41.5%), and median PFS was 5.5 months (0.5-31 months). Thirty-three of the 40 patients with irAEs had objective response (82.5%) in contrast with 11 of the 66 cases without irAEs (16.6%) (OR 23.5, P < 0.000001). PFS in patients with irAEs was 10 months and 3 months in those without irAEs (HR 2.2, P = 0.016). OS in patients with irAEs was 32 months and 22 in those without irAEs, without statistically significant differences. CONCLUSION: In advanced cancer treated with single-agent anti-PD-1 antibodies, patients with irAEs showed a markedly improved efficacy over patients without irAEs (ORR of 82.5% and PFS of 10 months vs ORR of 16.6% and PFS of 3 months). Future studies of anti-PD-1 immune-therapy should address this association to explore the underlying biological mechanisms of efficacy.
引用
- Rogado J, Sánchez-Torres JM, Romero-Laorden N, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019. PMID: 30682533. doi:10.1016/j.ejca.2018.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。